Bellevue Group’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-4,460,693
| Closed | -$24.2M | – | 164 |
|
|
2024
Q4 | $24.2M | Hold |
4,460,693
| – | – | 0.47% | 52 |
|
|
2024
Q3 | $32.2M | Sell |
4,460,693
-4,000
| -0.1% | -$36.6K | 0.52% | 59 |
|
|
2024
Q2 | $48.5M | Sell |
4,464,693
-851
| -0% | -$10.9K | 0.79% | 31 |
|
|
2024
Q1 | $83.7M | Buy |
4,465,544
+952,193
| +27% | +$22M | 1.28% | 22 |
|
|
2023
Q4 | $76.1M | Hold |
3,513,351
| – | – | 1.16% | 25 |
|
|
2023
Q3 | $72.3M | Buy |
3,513,351
+398,976
| +13% | +$11.5M | 1.16% | 24 |
|
|
2023
Q2 | $146M | Buy |
3,114,375
+24,375
| +0.8% | +$1.21M | 2.09% | 11 |
|
|
2023
Q1 | $130M | Buy |
3,090,000
+120,722
| +4% | +$5.19M | 1.88% | 13 |
|
|
2022
Q4 | $113M | Sell |
2,969,278
-1,400
| -0% | -$53.5K | 1.5% | 19 |
|
|
2022
Q3 | $116M | Sell |
2,970,678
-2,500
| -0.1% | -$96.6K | 1.67% | 14 |
|
|
2022
Q2 | $96M | Sell |
2,973,178
-79,226
| -3% | -$2.66M | 1.36% | 17 |
|
|
2022
Q1 | $101M | Sell |
3,052,404
-175,600
| -5% | -$6.6M | 1.17% | 28 |
|
|
2021
Q4 | $137M | Buy |
3,228,004
+19,000
| +0.6% | +$796K | 1.42% | 20 |
|
|
2021
Q3 | $142M | Buy |
3,209,004
+844,800
| +36% | +$38.7M | 1.44% | 17 |
|
|
2021
Q2 | $134M | Buy |
2,364,204
+553,500
| +31% | +$39.1M | 1.31% | 20 |
|
|
2021
Q1 | $136M | Buy |
1,810,704
+243,200
| +16% | +$19.9M | 1.43% | 18 |
|
|
2020
Q4 | $136M | Sell |
1,567,504
-12,000
| -0.8% | -$884K | 1.55% | 17 |
|
|
2020
Q3 | $96.5M | Buy |
1,579,504
+164,000
| +12% | +$8.31M | 1.33% | 20 |
|
|
2020
Q2 | $58.9M | Sell |
1,415,504
-2,600
| -0.2% | -$94.4K | 0.83% | 33 |
|
|
2020
Q1 | $40.7M | Buy |
1,418,104
+109,250
| +8% | +$6.33M | 0.79% | 36 |
|
|
2019
Q4 | $94.5M | Buy |
1,308,854
+5,350
| +0.4% | +$658K | 1.5% | 19 |
|
|
2019
Q3 | $183M | Sell |
1,303,504
-17,900
| -1% | -$2.99M | 3.4% | 5 |
|
|
2019
Q2 | $242M | Buy |
1,321,404
+1,305,104
| +8,007% | +$223M | 4.13% | 5 |
|
|
2019
Q1 | $2.59M | Buy |
16,300
+5,700
| +54% | +$825K | 0.14% | 99 |
|
|
2018
Q4 | $1.02M | Sell |
10,600
-600
| -5% | -$68.7K | 0.07% | 115 |
|
|
2018
Q3 | $1.58M | Sell |
11,200
-900
| -7% | -$139K | 0.1% | 110 |
|
|
2018
Q2 | $1.89M | Sell |
12,100
-350
| -3% | -$54.9K | 0.16% | 91 |
|
|
2018
Q1 | $2M | Sell |
12,450
-200
| -2% | -$34K | 0.2% | 79 |
|
|
2017
Q4 | $2.08M | Buy |
+12,650
| New | +$1.23M | 0.22% | 76 |
|
Other funds holding SAGE
Bellevue Group's SAGE Position: Q1 2025 in Review
Bellevue Group sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 4,460,693 shares — an estimated $24.2M sold.
Bellevue Group first reported a position in SAGE in Q4 2017 and held it in 29 quarters. The position peaked at $242M in Q2 2019. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.
- Bellevue Group reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
- Bellevue Group sold 4,460,693 Sage Therapeutics shares in Q1 2025, an estimated $24.2M.
- Bellevue Group first reported a position in Sage Therapeutics in Q4 2017 and held it in 29 quarters.
- Bellevue Group's Sage Therapeutics position peaked at $242M in Q2 2019.
- 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.
Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.